Skip to main content
Premium Trial:

Request an Annual Quote

Harvard Bio Stock Regains Lost Ground From Tumble Following Last Week s Q3 Report

NEW YORK, Nov. 3 (GenomeWeb News) - Shares in Harvard Bioscience closed up 6.56 percent on Wednesday, regaining ground lost since the company released lackluster revenue growth on Oct. 29.


The firm's shares closed up at $4.20 on the Nasdaq exchange, eclipsing the closing price for its shares just before it released its Q3 results on Oct. 29. The third-quarter earning sreport caused the company's shares to tumble 

more that 9 percent to close $3.70 on Oct. 29 from $4 the day before.


Last week, Harvard said its poorly performing Genomic Solutions unit acted as ballast on third-quarter revenue. The firm posted Q3 revenue of $23.2 million, up from $21.1 million in the comparable period a year ago. Harvard also lowered by $2.2 million its revenue outlook for the fourth quarter.

The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.